Evidence map›Paper›PMID 41555464›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026

MRI-based patient selection for active surveillance in prostate cancer using U-Found: a generalized deep learning model.

Noah C Lowry, Adrian L Breto, Veronica Wallaengen, Ahmad Algohary, Nicolas Tapia-Stoll, Sandra M Gaston, Nachiketh S Prakash, Pedro F S Freitas, Oleksandr N Kryvenko, Patricia Castillo and 13 more

Abstract read
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Noah C Lowry *Department of Radiation Oncology, University of Miami Miller School of Medicine, 1475 NW 12th St, Miami, FL, 33136, USA.
Adrian L Breto *Department of Radiation Oncology, University of Miami Miller School of Medicine, 1475 NW 12th St, Miami, FL, 33136, USA.
Veronica Wallaengen *Department of Radiation Oncology, University of Miami Miller School of Medicine, 1475 NW 12th St, Miami, FL, 33136, USA.
Ahmad AlgoharyDepartment of Radiation Oncology, University of Miami Miller School of Medicine, 1475 NW 12th St, Miami, FL, 33136, USA.
Nicolas Tapia-StollDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Sandra M GastonDepartment of Radiation Oncology, University of Miami Miller School of Medicine, 1475 NW 12th St, Miami, FL, 33136, USA.
Nachiketh S PrakashDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Pedro F S FreitasDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Oleksandr N KryvenkoDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Patricia CastilloDepartment of Radiology, University of Miami Miller School of Medicine, Miami, FL, USA.
Joel SaltzDepartment of Biomedical Informatics, Stony Brook University, New York, NY, USA.
Tahsin KurcDepartment of Biomedical Informatics, Stony Brook University, New York, NY, USA.
Chad R RitchDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Bruno NaharDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Mark L GonzalgoDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Dipen J ParekhDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Brandon MahalDepartment of Radiation Oncology, University of Miami Miller School of Medicine, 1475 NW 12th St, Miami, FL, 33136, USA.
Benjamin O SpielerDepartment of Radiation Oncology, University of Miami Miller School of Medicine, 1475 NW 12th St, Miami, FL, 33136, USA.
Alan Dal PraDepartment of Radiation Oncology, University of Miami Miller School of Medicine, 1475 NW 12th St, Miami, FL, 33136, USA.
Matthew C AbramowitzDepartment of Radiation Oncology, University of Miami Miller School of Medicine, 1475 NW 12th St, Miami, FL, 33136, USA.
Alan PollackDepartment of Radiation Oncology, University of Miami Miller School of Medicine, 1475 NW 12th St, Miami, FL, 33136, USA.
Sanoj PunnenDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Radka StoyanovaDepartment of Radiation Oncology, University of Miami Miller School of Medicine, 1475 NW 12th St, Miami, FL, 33136, USA. rstoyanova@med.miami.edu.

Funding

UM Calabresi Clinical Oncology Research Career Development AwardK12CA226330 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Alan Pollack · 2018 to 2026
$5.1M
Longitudinal Imaging and Liquid Biopsy Markers of Prostate Cancer Radiotherapy OutcomesR01CA294824 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Alan Pollack, Benjamin Oren Spieler · 2025 to 2026
$1.1M
NCI NIH HHS K12 CA226330NCI NIH HHS R01 CA294824
6 · The paper itself

Abstract

backgroundCurrent MRI prostate cancer risk assessment methods focus mainly on detecting tumor lesions, ignoring the prostate gland macro-environment which may also impact disease progression. A generalized deep-learning model for prostate may help capture these gland-level characteristics through deep embeddings which can be used for a variety of downstream tasks. This study aims to assess whether U-Found, a generalized multiparametric (mp)MRI-based model, offers added value in predicting histopathological progression in active surveillance (AS) patients. The prostate macro-environment, captured in U-Found embeddings, is hypnotized to play a significant role in differentiating patients who progress to definitive treatment from those whose tumor is kept at bay.

methodsU-Found was trained on a dataset comprising over 3000 mpMRIs from in-house and public sources using self-supervised learning. Axial slices were represented in a 128-dimentional space. The physical interpretation of the embeddings was explored by investigating images that are closest to the centroid of embeddings clusters. U-Found was tested on a downstream task: identifying cancer in an independent dataset (publicly available UCLA dataset, n = 1,151). To determine the added value of U-Found embeddings to clinical and intratumoral radiomics features, we compared models for predicting histopathological progression in 144 participants of a prospective AS trial. In addition, associations between U-Found embeddings and lesion- and prostate radiomics were investigated.

resultsOur findings suggest that U-Found captures key characteristics of the prostate gland’s macro-environment. U-Found successfully detected cancer in an independent UCLA dataset without being explicitly trained for lesion detection (AUC = 0.79). The prediction model incorporating a combination of clinical variables, mpMRI-derived intratumoral radiomics features and deep embeddings generated by U-Found achieved AUC = 0.86, outperforming models solely based on clinical and/or radiomics features. There were clear associations between U-Found embeddings and radiomics features.

conclusionsU-Found was designed as a generalized self-supervised foundation model for prostate imaging, enabling the model to learn intrinsic imaging structures. We demonstrate that U-Found embeddings capture key features of the prostate macro-environment, which appear to contribute to disease progression, albeit to a lesser extent than tumor-specific imaging features.

Indexed as

Deep LearningMagnetic Resonance ImagingMultiparametric Magnetic Resonance ImagingPatient SelectionProstatic NeoplasmsWatchful WaitingAgedDisease ProgressionHumansMaleMiddle AgedActive SurveillanceApparent Diffusion CoefficientContrastive learningDeep learningDiffusion-weighted imagingFoundation modelsMultiparametric (mp)MRIProstate cancerUnsupervised deep learning

Identifiers

PMID41555464
PMCPMC12896071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.